ACLX News and Press, Arcellx Inc. From 01/09/23

Summary Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead. Arcellx goes up against Johnson & Johnson's formidable carvykti, but now it has help. Arcellx, Inc. ( ACLX ) is up 83% since my bullish coverage f...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it’s teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ). Together,...

Arcellx ( NASDAQ: ACLX ) on Friday said it would co-develop and co-commercialize its lead late-stage product candidate CART-ddBCMA for the treatment of multiple myeloma with Kite, a Gilead Sciences ( NASDAQ: GILD ) company. Under the global strategic collaboration, ACLX wi...

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress PR Newswire -- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses o...

-- Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to ...

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma PR Newswire -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading...

Arcellx press release ( NASDAQ: ACLX ): Q3 GAAP EPS of -$2.12. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months. For further details ...

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress PR Newswire -- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA  -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 6...

The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Corporate Presentation - Slideshow